Bayer AG NA Cash Flow Conversion Efficiency
Bayer AG NA cash flow conversion efficiency. Based on the latest financial reports, Bayer AG NA (BAYN) has a cash flow conversion efficiency ratio of 0.142x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€3.69 Billion ≈ $4.31 Billion USD) by net assets (€26.06 Billion ≈ $30.47 Billion USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Bayer AG NA (1998–2025)
Cash flow conversion efficiency of Bayer AG NA from 1998 to 2025. This chart illustrates how Bayer AG NA's cash flow conversion efficiency has evolved over time, based on yearly financial data. View Bayer AG NA (BAYN) stock price for real-time trading data and today's change.
Bayer AG NA Cash Flow Conversion Ratio Explained
Bayer AG NA cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Bayer AG NA Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bayer AG NA ranked by their cash flow conversion efficiency. Also see BAYN market cap overview for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KB Financial Group
KO:105560
|
0.025x |
|
Carnival Corporation
NYSE:CCL
|
0.097x |
|
Legrand SA
PA:LR
|
0.041x |
|
Old Dominion Freight Line Inc
NASDAQ:ODFL
|
0.060x |
|
Prudential Financial Inc
NYSE:PRU
|
-0.014x |
|
WEC Energy Group Inc
NYSE:WEC
|
0.084x |
|
UltraTech Cement Limited
NSE:ULTRACEMCO
|
0.073x |
|
PTT Public Company Limited
BK:PTT
|
0.031x |
Annual Cash Flow Conversion Efficiency for Bayer AG NA (1998–2025)
The table below shows the annual cash flow conversion efficiency of Bayer AG NA from 1998 to 2025. Review Bayer AG NA free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €26.06 Billion ≈ $30.47 Billion |
€4.57 Billion ≈ $5.34 Billion |
0.175x | -23.72% |
| 2024-12-31 | €32.05 Billion ≈ $37.46 Billion |
€7.37 Billion ≈ $8.61 Billion |
0.230x | +48.63% |
| 2023-12-31 | €33.08 Billion ≈ $38.67 Billion |
€5.12 Billion ≈ $5.98 Billion |
0.155x | -15.10% |
| 2022-12-31 | €38.93 Billion ≈ $45.51 Billion |
€7.09 Billion ≈ $8.29 Billion |
0.182x | +18.76% |
| 2021-12-31 | €33.17 Billion ≈ $38.78 Billion |
€5.09 Billion ≈ $5.95 Billion |
0.153x | -3.93% |
| 2020-12-31 | €30.70 Billion ≈ $35.89 Billion |
€4.90 Billion ≈ $5.73 Billion |
0.160x | -7.53% |
| 2019-12-31 | €47.52 Billion ≈ $55.55 Billion |
€8.21 Billion ≈ $9.59 Billion |
0.173x | +0.68% |
| 2018-12-31 | €46.15 Billion ≈ $53.95 Billion |
€7.92 Billion ≈ $9.26 Billion |
0.172x | -22.26% |
| 2017-12-31 | €36.86 Billion ≈ $43.09 Billion |
€8.13 Billion ≈ $9.51 Billion |
0.221x | -22.56% |
| 2016-12-31 | €31.90 Billion ≈ $37.29 Billion |
€9.09 Billion ≈ $10.63 Billion |
0.285x | +5.23% |
| 2015-12-31 | €25.45 Billion ≈ $29.75 Billion |
€6.89 Billion ≈ $8.06 Billion |
0.271x | -5.77% |
| 2014-12-31 | €20.22 Billion ≈ $23.64 Billion |
€5.81 Billion ≈ $6.79 Billion |
0.287x | +15.61% |
| 2013-12-31 | €20.80 Billion ≈ $24.32 Billion |
€5.17 Billion ≈ $6.05 Billion |
0.249x | +1.84% |
| 2012-12-31 | €18.57 Billion ≈ $21.71 Billion |
€4.53 Billion ≈ $5.30 Billion |
0.244x | -7.05% |
| 2011-12-31 | €19.27 Billion ≈ $22.53 Billion |
€5.06 Billion ≈ $5.92 Billion |
0.263x | -14.06% |
| 2010-12-31 | €18.90 Billion ≈ $22.09 Billion |
€5.77 Billion ≈ $6.75 Billion |
0.306x | +7.72% |
| 2009-12-31 | €18.95 Billion ≈ $22.16 Billion |
€5.38 Billion ≈ $6.28 Billion |
0.284x | +28.45% |
| 2008-12-31 | €16.34 Billion ≈ $19.10 Billion |
€3.61 Billion ≈ $4.22 Billion |
0.221x | -13.28% |
| 2007-12-31 | €16.82 Billion ≈ $19.67 Billion |
€4.28 Billion ≈ $5.01 Billion |
0.255x | -22.14% |
| 2006-12-31 | €12.85 Billion ≈ $15.02 Billion |
€4.20 Billion ≈ $4.91 Billion |
0.327x | +1.90% |
| 2005-12-31 | €10.90 Billion ≈ $12.75 Billion |
€3.50 Billion ≈ $4.09 Billion |
0.321x | +62.15% |
| 2004-12-31 | €12.37 Billion ≈ $14.46 Billion |
€2.45 Billion ≈ $2.86 Billion |
0.198x | -25.85% |
| 2003-12-31 | €12.31 Billion ≈ $14.40 Billion |
€3.29 Billion ≈ $3.84 Billion |
0.267x | -6.66% |
| 2002-12-31 | €15.47 Billion ≈ $18.08 Billion |
€4.42 Billion ≈ $5.17 Billion |
0.286x | +26.11% |
| 2001-12-31 | €17.05 Billion ≈ $19.93 Billion |
€3.87 Billion ≈ $4.52 Billion |
0.227x | +20.15% |
| 2000-12-31 | €16.42 Billion ≈ $19.20 Billion |
€3.10 Billion ≈ $3.62 Billion |
0.189x | -11.92% |
| 1999-12-31 | €15.18 Billion ≈ $17.75 Billion |
€3.25 Billion ≈ $3.80 Billion |
0.214x | -3.86% |
| 1998-12-31 | €12.78 Billion ≈ $14.94 Billion |
€2.85 Billion ≈ $3.33 Billion |
0.223x | -- |
About Bayer AG NA
Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women's health care; speci… Read more